(2)
Merger of 10 Privately Held Biotech Companies with Highly Validated Programs Led by Industry Leading Teams to Operate Under Centessa Umbrella
Company Founded by Medicxi with Financing Led by General Atlantic, and Co-led by Vida Ventures and Janus Henderson Investors
Saurabh Saha, M.D., Ph.D., Former Senior Vice President, R&D, and Global Head of Translational Medicine at Bristol Myers Squibb, Appointed as Chief Executive Officer
Moncef Slaoui, Ph.D., Former Chief Scientific Advisor of Operation Warp Speed, Former Chairman of R&D at GlaxoSmithKline, Partner at Medicxi, Appointed as Chief Scientific Officer, Advisor
Centessa Pharmaceuticals ( Centessa ) launched today as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs. Centessa s asset-centric R&D model applied at scale has assembled best-in-class or first-in-class assets, each of which is led by specialized teams committed to accelerate development and reshap
Former Operation Warp Speed leader lands post at drug firm with ties to Cambridge Moncef Slaoui will serve as chief scientific officer and paid adviser to Centessa Pharmaceuticals
By Jonathan Saltzman Globe Staff,Updated February 16, 2021, 6:30 a.m.
Email to a Friend
Moncef Slaoui, former chief scientific adviser to Operation Warp Speed, spoke at the White House in January.Chris Kleponis/Photographer: Chris Kleponis/Pol
Moncef Slaoui, who recently stepped down as chief scientific adviser to Operation Warp Speed, has a new gig at a drug firm that considers Massachusetts its home.
Slaoui will serve as chief scientific officer and paid adviser to Centessa Pharmaceuticals, a company formed by the merger of 10 privately held biotech startups. A news release on Tuesday announcing the merger described Centassa as âheadquartered in Cambridge,â but it will operate largely online. The 10 firms have about 150 employees and consultants around the world, including in the United K